Prof. Schneider explains TCAR in high-risk carotid disease

At PVI 2025, Prof. Peter Schneider reflected on a session dedicated to carotid artery disease, a field that has seen rapid growth in new data, trials, technologies, and techniques.

He highlighted the role of transcarotid artery revascularisation (TCAR) in high-risk patients—particularly those with recent neurological symptoms or contralateral carotid artery occlusion—where flow reversal provides robust protection during stenting.

Drawing on large-scale real-world data from the Vascular Quality Initiative (VQI), now part of the National Cardiovascular Data Registry (NCDR), he explained that outcomes in these patients are comparable, or even slightly superior to carotid endarterectomy (CEA). For recently symptomatic patients, TCAR offers strong protection in the 2- to 14-day period after stroke, with results favorable compared with transfemoral stenting and similar to CEA.

Explore the data behind TCAR in high-risk carotid patients!